Geiger Pamina, Mayer Barbara, Wiest Irmi, Schulze Sandra, Jeschke Udo, Weissenbacher Tobias
Department of Obstetrics and Gynecology, LMU Munich-Innenstadt, Maistrasse 11, 80337, München, Germany.
Department of General, Visceral and Transplantation Surgery, Hospital of the LMU Munich, Marchioninistr 15, 81377, Munich, Germany.
BMC Cancer. 2016 Nov 8;16(1):870. doi: 10.1186/s12885-016-2915-8.
Galectin-1 (gal-1) belongs to the family of β-galactoside-binding proteins which primarily recognizes the Galβ1-4GlcNAc sequences of oligosaccharides associated with several cell surface glycoconjugates. The lectin recognizes correspondent glycoepitopes on human breast cancer cells. Galectin-1 is expressed both in normal and malignant tissues. Lymphatic organs naturally possessing high rates of apoptotic cells, express high levels of Galectin-1. Furthermore galectin-1 can initiate T cell apoptosis. Binding of galectin-1 to trophoblast tumor cells presenting the oncofetal Thomsen-Friedenreich (TF) carbohydrate antigen inhibits tumor cell proliferation. In this study we examined the impact galectin-1 has in vitro on cell proliferation, apoptotic potential and metabolic activity of MCF-7 and T-47D breast cancer cells in dependence to their expression of the Thomsen-Friedenreich (TF) tumor antigen.
For proliferation and apoptosis assays cells were grown in presence of 10, 30 and 60 μg gal-1/ml medium. Cell proliferation was determined by a BrdU uptake ELISA. Detection of apoptotic cells was done by M30 cyto death staining, in situ nick translation and by a nucleosome ELISA method. Furthermore we studied the impact galectin-1 has on the metabolic activity of MCF-7 and T-47D cells in a homotypic three-dimensional spheroid cell culture model mimicking a micro tumour environment.
Gal-1 inhibited proliferation of MCF-7 cells (strong expression of the TF epitope) but did not significantly change proliferation of T-47D cells (weak expression of the TF epitope). The incubation of MCF-7 cells with gal-1 raised number of apoptotic cells significantly. Treating the spheroids with 30 μg/ml galectin-1 in addition to standard chemotherapeutic regimes (FEC, TAC) resulted in further suppression of the metabolic activity in MCF-7 cells whereas T-47D cells were not affected.
Our results demonstrate that galectin-1 can inhibit proliferation und metabolic cell activity and induce apoptosis in breast tumor cell lines with high expression levels of the Thomsen-Friedenreich (TF) antigen in monolayer and spheroid cell culture models.
半乳糖凝集素-1(gal-1)属于β-半乳糖苷结合蛋白家族,主要识别与几种细胞表面糖缀合物相关的寡糖的Galβ1-4GlcNAc序列。该凝集素可识别人类乳腺癌细胞上相应的糖表位。半乳糖凝集素-1在正常组织和恶性组织中均有表达。天然具有高凋亡细胞率的淋巴器官表达高水平的半乳糖凝集素-1。此外,半乳糖凝集素-1可引发T细胞凋亡。半乳糖凝集素-1与呈现癌胚性Thomsen-Friedenreich(TF)碳水化合物抗原的滋养层肿瘤细胞结合可抑制肿瘤细胞增殖。在本研究中,我们检测了半乳糖凝集素-1在体外对MCF-7和T-47D乳腺癌细胞的增殖、凋亡潜能及代谢活性的影响,这取决于它们对Thomsen-Friedenreich(TF)肿瘤抗原的表达。
为进行增殖和凋亡检测,细胞在含有10、30和60μg gal-1/ml培养基的条件下培养。通过BrdU摄取ELISA法测定细胞增殖。通过M30细胞死亡染色、原位缺口平移和核小体ELISA法检测凋亡细胞。此外,我们在模拟微肿瘤环境的同型三维球体细胞培养模型中研究了半乳糖凝集素-1对MCF-7和T-47D细胞代谢活性的影响。
Gal-1抑制MCF-7细胞(TF表位强表达)的增殖,但对T-47D细胞(TF表位弱表达)的增殖无显著影响。用gal-1孵育MCF-7细胞可显著增加凋亡细胞数量。除标准化疗方案(FEC、TAC)外,用30μg/ml半乳糖凝集素-1处理球体可进一步抑制MCF-7细胞的代谢活性,而T-47D细胞不受影响。
我们的结果表明,在单层和球体细胞培养模型中,半乳糖凝集素-1可抑制高表达Thomsen-Friedenreich(TF)抗原的乳腺癌细胞系的增殖和代谢细胞活性,并诱导其凋亡。